![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
INSPIRING: SAFETY AND EFFICACY OF DOLUTEGRAVIR-BASED
ART IN TB/HIV CO-INFECTED ADULTS AT WEEK 48
|
|
|
Reported by Jules Levin
22nd International AIDS Conference, Amsterdam, Netherlands, July 23-27, 2018
Dooley KE,1 Kaplan R,2 Mwelase T,3 Grinsztejn B,4 Ticona E,5 Lacerda M,6
Sued O,7 Belonosova E,8 Ait-Khaled M,9 Angelis K,10 Brown D,11 Singh R,12 Talarico C,13 Tenorio A,13 Keegan M,9 Aboud M9
1Johns Hopkins University School of Medicine, Baltimore, MD, USA; 2Desmond Tutu HIV Foundation, Cape Town, South Africa; 3Clinical HIV Research Unit, Johannesburg, South Africa; 4Instituto de Pesquisa Clinica Evandro Chagas FIOCRUZ, Rio de Janeiro, Brazil; 5Hospital Dos de Mayo, Lima, Peru; 6Fiocruz/Tropical Medicine Foundation Dr Heitor, Vieira Dourado, Manaus, Brazil; 7Fundacion Huesped, Bueno Aires, Argentina; 8Regional Center For Prevention and Treatment of AIDS and Infectious Diseases, Russia; 9ViiV Healthcare, Brentford, UK; 10GlaxoSmithKline, Stockley Park, UK; 11ViiV Healthcare, Melbourne, Australia; 12GlaxoSmithKline, Upper Merion, PA, USA; 13ViiV Healthcare, Research Triangle Park, NC, USA
![0726181](../images%20/072618/072618-6/0726181.gif)
![0726182](../images%20/072618/072618-6/0726182.gif)
![0726183](../images%20/072618/072618-6/0726183.gif)
![0726184](../images%20/072618/072618-6/0726184.gif)
![0726185](../images%20/072618/072618-6/0726185.gif)
![0726186](../images%20/072618/072618-6/0726186.gif)
![0726187](../images%20/072618/072618-6/0726187.gif)
![0726188](../images%20/072618/072618-6/0726188.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|